I agree that Nader should be commended for saving

New Post Public Reply Private Reply Replies (1) Message Board
generactor TechGuru #116190
645
I agree that Nader should be commended for saving leronlimab and I never doubted his passion for helping patients but...

If he had quit in late 2019 like he contemplated, I think the company probably would have been in a lot better shape.

He was an amateur, consistently had unrealistic ambitions and could be guilty of short-term thinking. The embarrassingly early cancer BTD submission in early 2020 and trying to ram the obviously unfinished BLA through (I don't care what Amarex did or didn't do, he decided to submit it) were perfect examples. Then in late summer 2020 he admitted that he had 2 strikes against him with the FDA, and it's obvious in hindsight that both of the strikes were unforced errors.

Ask yourself, where would the company have been under his leadership without covid? After the BLA fiasco, it probably would have been bankrupt or John Fife would have wound up being our CEO and installing his relatives on the Board (that happened to another company, SDRG)

All of this is water under the bridge now and I'm very excited about the future but without covid Nader would have likely screwed us all so it was long past time for him to go, and here's to the future being golden with our second chance.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Pursuing Justice: WPP plc Investors' Class Action Pathway

Updated Category News Views 171

Investors Encouraged to Act Before Class Action Deadline WPP plc is making headlines as investors are reminded of the critical timelines regarding a securities class action lawsuit. If you purchased American Depositary Shares (ADS) for WPP plc within a specific class period earlier this year, know that you have the opportunity to join a lawsuit that could secure...

Continue Reading
Innovative Therapies in HER2-Positive Gastric Cancer Pipeline

Updated Category News Views 220

Insights into the HER2-Positive Gastric Cancer Landscape The HER2-positive gastric cancer market is on the rise, fueled by an increasing number of patients who can benefit from targeted treatments. This surge results from heightened global disease prevalence and advancements in HER2 testing. As a result, more patients are being identified as candidates for therapies...

Continue Reading
Transforming Entertainment: TRWD's Path to Nationwide Success

Updated Category News Views 134

Revolutionizing a Fragmented Entertainment Industry Tradewinds Universal, Inc. (OTC: TRWD) stands at the brink of transformation within a significant and fragmented entertainment landscape. This sector includes over 3,000 independently owned venues, contributing to a market size that exceeds $10 billion annually. With these numbers indicating a ripe opportunity, TRWD...

Continue Reading
Understanding Whales' Strategies With Rivian Automotive Options

Updated Category News Views 234

Understanding Whales' Strategies in Rivian Automotive Options Recent actions by financial giants have signaled a notable bearish trend towards Rivian Automotive (NASDAQ: RIVN). A thorough analysis of options trading activity reveals intriguing insights into how these major players are approaching the market. In our study, we uncovered nine unusual trades that exemplify...

Continue Reading
Fortive Welcomes Shar Dubey as New Board Chair for Future Growth

Updated Category News Views 233

Fortive Corporation Announces New Chair of the Board Fortive Corporation (NYSE: FTV) has made an important announcement regarding its Board of Directors. The company has appointed Sharmistha "Shar" Dubey as the new Chair of the Board, succeeding Alan G. Spoon. This transition comes as Spoon has decided to retire and not seek reelection at the upcoming Annual General...

Continue Reading